Autolus Therapeutics (AUTL): Deep Track Capital, LP reduced its stake -997K shares
Deep Track Capital, LP reduced its stake in Autolus Therapeutics, per its Q2 2025 13F.
- 16.9M
- Shares reported · -997K vs prior quarter
- 1.2%
- Disclosed portfolio weight
- $38.4M
- Reported value
- Holdings as of
- Jun 30, 2025
- Filed
- Aug 14, 2025
What stands out in this filing
- 17,849,482 shares in Q1 2025, 16,852,147 now (−5.6% in share count).
- Reported at $38.4M, 1.23% of the portfolio value in this 13F filing.
- 1 other tracked manager reported the same kind of change for Q2 2025.
Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
What came next
- Nov 12, 2025Company filing · Form 8-K · Results, Executive changeChanged a top executive or board member, and reported its results (and 1 more item)“On November 7, 2025, Mr. Dolski notified the Company of his intention to resign as principal accounting officer of the Company; Mr. Dolski will continue to serve as the Company’s Chief Financial Officer and Principal Financial Officer.”
- Dec 1, 2025Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On December 1, 2025, Autolus Therapeutics plc (the “Company”) announced that its board of directors (the “Board”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Ryan Richardson to serve as a Class I director of the Company, effective December 1, 2025 and continuing until the Company’s 2028 annual general meeting of shareholders, or until his successor has been…”
How to read SEC Form 13F-HR
Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.
Full guide: What is an SEC Form 13F?
What else is on file for Autolus Therapeutics
For Autolus Therapeutics, OQRO holds 1 insider filing (SEC Form 4 or Form 144) and 2 fund holdings reports (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its AUTL page.
How this filing works
Explore the data
Common questions
What does this filing report about Autolus Therapeutics (AUTL) stock?
Deep Track Capital, LP reduced its stake in Autolus Therapeutics, per its Q2 2025 13F. Now 16.9M shares, $38.4M reported value, 1.2% of disclosed portfolio.
When did it happen, and when was it made public?
Holdings as of: Jun 30, 2025. Filed: Aug 14, 2025.
What stands out in this filing?
17,849,482 shares in Q1 2025, 16,852,147 now (−5.6% in share count). Reported at $38.4M, 1.23% of the portfolio value in this 13F filing. 1 other tracked manager reported the same kind of change for Q2 2025.
Is this a trade made on a known date?
No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.
Where does this information come from?
From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Autolus Therapeutics recently?
For Autolus Therapeutics, OQRO holds 1 insider filing (SEC Form 4 or Form 144) and 2 fund holdings reports (13F) dated in the last 90 days. They are listed on the AUTL page.
Does this mean AUTL stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Autolus Therapeutics
- SEC Schedule 13DNov 10, 2026
- SEC Form 13F-HRNov 6, 2026
- SEC Form 4Sep 3, 2026
- SEC Form 13F-HRNov 14, 2025
- SEC Form 13F-HRMay 15, 2025
- SEC Form 13F-HRFeb 14, 2025
Everything OQRO holds on this company is on its AUTL page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
